India Approves Two New Vaccines As Well As Merck’s Covid Pill

The Centers for Disease Control and Prevention (CDC) has approved two additional vaccines and one antiviral medicine to aid in the fight against the COVID-19 pandemic.

New Delhi (India)

Two additional vaccines and one antiviral medicine were approved by the centre today to aid in the fight against the COVID-19 pandemic. The two most recent vaccinations to be licenced by India are Corbevax and Covovax. The antiviral medicine Molnupiravir, according to Health Minister Mansukh Mandaviya, should only be administered in an emergency.
Corbevax is India’s first “RBD protein sub-unit vaccine,” according to the Health Minister. It was developed by Biological-E, a Hyderabad-based firm. “It’s a hat-trick to remember!” Mr Mandaviya stated, “This is India’s third vaccination.” Covaxin from Bharat Biotech and Covishield from the Serum Institute of India are the other two Indian vaccines.

SII, based in Pune, will manufacture Covovax, a nanoparticle vaccine.

According to the Health Minister, 13 companies will manufacture molnupiravir, an antiviral medication, for limited usage in emergency settings to treat adult COVID-19 patients with a high risk of disease progression.


The eight COVID-19 vaccines that have got emergency use authorization from India’s drug regulator are Covishield, Covaxin, ZyCoV-D, Sputnik V, Moderna, Johnson and Johnson, Corbevax, and Covovax.

In partnership with Cipla, Mylan, Torrent, Emcure, and Sun Pharma, Dr. Reddy’s Laboratories presented a proposal for the antiviral medication Molnupiravir to be approved for use in emergency situations.

The US Food and Drug Administration recently approved Merck’s Molnupiravir for the treatment of mild-to-moderate COVID-19 cases in adults at risk of severe illness. Prior to that, the United Kingdom gave Merck’s coronavirus antiviral, the first tablet proved to effectively treat COVID-19, conditional approval in November.

In a clinical trial of high-risk persons in the early stages of sickness, Merck’s medication was proven to reduce hospitalizations and fatalities by roughly 30%.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button